Key Highlights

  • Research and development expenses were USD 64.4 million in the third quarter.
  • Cash, cash equivalents and investments were USD 591.4 million at September 30, 2026.
  • The IPO delivered net proceeds of USD 422.5 million.
  • The Phase 3 trial of danicamtiv began in August 2026.

Kardigan (NASDAQ:KARD) filed its Quarterly Report for the period ended September 30, 2026, its first since completing its initial public offering on June 22, 2026. Loss per share was USD 0.64, against an estimate of USD 0.78. The company is a clinical-stage precision therapeutics company developing medicines for specific cardiovascular diseases where no approved treatments exist.

The company was incorporated in Delaware in August 2023 under the name EnCarda, Inc. It reported no Revenue figure for the period.

Research Spending and Pipeline Activity

Research and development expenses were USD 64.4 million for the three months ended September 30, 2026, compared with USD 49.1 million a year earlier, an increase of USD 15.2 million. Danicamtiv program expenses rose USD 4.2 million, reflecting the initiation of the Phase 3 clinical trial in August 2026. Ataciguat program expenses rose USD 3.4 million, reflecting continued Investment in that program.

For the nine months, Research and Development expenses were USD 165.8 million, against USD 103.8 million a year earlier, an increase of USD 62.0 million. The filing attributes the increase to expanded clinical activity across the pipeline, with danicamtiv program expenses up USD 26.9 million.

The filing names the Phase 2b KINSHIP-DCM trial of danicamtiv, the Phase 2b KATALYST-AV trial, the Phase 2 KARDINAL-ASH trial and the Phase 3 danicamtiv trial as ongoing. It also lists planned Phase 3 trials of ataciguat and tonlamarsen, if or when initiated. The company describes a goal of three medicines through pivotal studies in roughly four years, subject to regulatory approval.

Cash, Funding and Operating Costs

In connection with the IPO, the company received net proceeds of USD 422.5 million, after USD 32.2 million in Underwriting discounts and commissions and USD 5.3 million in other offering costs. As of September 30, 2026, it held cash, cash equivalents and investments of USD 591.4 million.

General and administrative expenses were USD 54.8 million for the nine months ended September 30, 2026, against USD 38.5 million a year earlier. The filing links the increase to expanded operating scale, continued advancement of the development portfolio and organizational growth.

Net cash used in Operating Activities was USD 167.2 million for the nine months, driven by a net loss of USD 230.9 million, partly offset by adjustments totaling USD 57.6 million. In the prior-year nine months, net cash used in operating activities was USD 99.3 million, with a net loss of USD 135.6 million.

Investing, Financing and Reported Reference Points

Net cash used in investing activities was USD 296.8 million for the nine months, against USD 123.5 million a year earlier. Net cash provided by financing activities was USD 433.8 million, compared with USD 343.1 million in the prior-year period.

The filing reports net losses of USD 191.9 million for the year ended December 31, 2025 and USD 88.7 million for 2024. The prior-year investing activity included the cash portion of the consideration paid for the Acquisition of Prolaio, Inc., of USD 4.0 million.

The reported items for the period are the IPO on June 22, 2026, the Phase 3 danicamtiv trial initiation in August 2026, research and development expenses of USD 64.4 million for the quarter and the balance of USD 591.4 million in cash, cash equivalents and investments. The company is listed on the Nasdaq Global Market.